Azienda Ospedaliera di Padova
aopd.veneto.itTotal trials
37
Active
10
Phase 3
2
Total enrollment
12,260
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Zanubrutinib Oral | — | — | — | — | — | 1 |
Next readouts
- 2031-03
Top conditions
- Sedation Complication3
- Liver Failure2
- Liver Diseases2
- Liver Neoplasms2
- Acute Kidney Injury2
- Liver Cirrhosis2
- Hepatitis C Virus1
- Chronic Liver Disease1
Frequently asked questions about Azienda Ospedaliera di Padova
- How many clinical trials does Azienda Ospedaliera di Padova have on ClinicalTrials.gov?
- Azienda Ospedaliera di Padova is listed as the lead sponsor on 37 clinical trials in ClinicalTrials.gov, 10 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Azienda Ospedaliera di Padova's trials are in Phase 3?
- 2 of Azienda Ospedaliera di Padova's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Azienda Ospedaliera di Padova focus on?
- Azienda Ospedaliera di Padova's most-studied conditions on ClinicalTrials.gov are Sedation Complication, Liver Failure, Liver Diseases, Liver Neoplasms, Acute Kidney Injury.
- When are Azienda Ospedaliera di Padova's next clinical trial readouts?
- Azienda Ospedaliera di Padova has 1 upcoming primary-completion readout tracked here; the soonest is “Zanubritnib and Anti-MAG Neuropathy”, expected around 2031-03.